The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SUNCAP, a phase II study with sunitinib and capecitabine in patients with metastatic colorectal cancer (MCRC) refractory to previous treatment with 5FU/irinotecan/oxaliplatin.
Benoit Samson
Disclosure not yet available
Jean Latreille
Disclosure not yet available
Nghia Trung Nguyen
Disclosure not yet available
Catherine Sperlich
Disclosure not yet available
Djamal Berbiche
Disclosure not yet available
Christophe Tournigand
Disclosure not yet available